90 related articles for article (PubMed ID: 26551340)
1. Patterns and Significance of PIM Kinases in Urothelial Carcinoma.
Albertson DJ; Schmidt RL; Bearss JJ; Tripp SR; Bearss DJ; Liu T
Appl Immunohistochem Mol Morphol; 2015; 23(10):717-23. PubMed ID: 26551340
[TBL] [Abstract][Full Text] [Related]
2. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.
Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB
Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177
[TBL] [Abstract][Full Text] [Related]
3. Significance of denuded urothelium in papillary urothelial lesions.
Owens CL; Epstein JI
Am J Surg Pathol; 2007 Feb; 31(2):298-303. PubMed ID: 17255776
[TBL] [Abstract][Full Text] [Related]
4. c-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas.
Shimada K; Nakamura M; Ishida E; Higuchi T; Tanaka M; Ota I; Konishi N
Am J Pathol; 2007 Sep; 171(3):1003-12. PubMed ID: 17690186
[TBL] [Abstract][Full Text] [Related]
5. Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions.
Moatamed NA; Vergara-Lluri ME; Lu D; Apple SK; Kerkoutian S; Rao JY
Hum Pathol; 2013 Nov; 44(11):2509-17. PubMed ID: 24029711
[TBL] [Abstract][Full Text] [Related]
6. [Molecular changes in development and progression of urothelial carcinoma].
Hartmann A
Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive micropapillary urothelial carcinoma: a clinicopathologic study of 18 cases.
Amin A; Epstein JI
Hum Pathol; 2012 Dec; 43(12):2124-8. PubMed ID: 22939957
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer.
Warnecke-Eberz U; Bollschweiler E; Drebber U; Metzger R; Baldus SE; Hölscher AH; Mönig S
Anticancer Res; 2009 Nov; 29(11):4451-5. PubMed ID: 20032391
[TBL] [Abstract][Full Text] [Related]
9. CD 10 expression intensity in various grades and stages of urothelial carcinoma of urinary bladder.
Atique M; Abbasi MS; Jamal S; Khadim MT; Akhtar F; Jamal N
J Coll Physicians Surg Pak; 2014 May; 24(5):351-5. PubMed ID: 24848395
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of PIM-1 is a potential biomarker in prostate carcinoma.
Xu Y; Zhang T; Tang H; Zhang S; Liu M; Ren D; Niu Y
J Surg Oncol; 2005 Dec; 92(4):326-30. PubMed ID: 16299799
[TBL] [Abstract][Full Text] [Related]
11. High-grade papillary urothelial carcinoma of the urinary tract: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center.
Chaux A; Karram S; Miller JS; Fajardo DA; Lee TK; Miyamoto H; Netto GJ
Hum Pathol; 2012 Jan; 43(1):115-20. PubMed ID: 21820145
[TBL] [Abstract][Full Text] [Related]
12. Pim-1 kinase expression during murine mammary development.
Gapter LA; Magnuson NS; Ng KY; Hosick HL
Biochem Biophys Res Commun; 2006 Jul; 345(3):989-97. PubMed ID: 16712793
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of ProEx C and ImmunoCyt/uCyt assays in atypical urine cytology.
Vergara-Lluri ME; Hu E; Rao JY; Levin M; Apple SK; Moatamed NA
Arch Pathol Lab Med; 2014 Sep; 138(9):1215-22. PubMed ID: 25171704
[TBL] [Abstract][Full Text] [Related]
14. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer.
Valdman A; Fang X; Pang ST; Ekman P; Egevad L
Prostate; 2004 Sep; 60(4):367-71. PubMed ID: 15264249
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Pim-1 is associated with poor prognosis in patients with esophageal squamous cell carcinoma.
Liu HT; Wang N; Wang X; Li SL
J Surg Oncol; 2010 Nov; 102(6):683-8. PubMed ID: 20544717
[TBL] [Abstract][Full Text] [Related]
16. Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma.
Hoang LL; Tacha D; Bremer RE; Haas TS; Cheng L
Appl Immunohistochem Mol Morphol; 2015; 23(10):711-6. PubMed ID: 25611245
[TBL] [Abstract][Full Text] [Related]
17. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis.
Wang Z; Bhattacharya N; Weaver M; Petersen K; Meyer M; Gapter L; Magnuson NS
J Vet Sci; 2001 Dec; 2(3):167-79. PubMed ID: 12441685
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma.
Downes MR; Torlakovic EE; Aldaoud N; Zlotta AR; Evans AJ; van der Kwast TH
J Clin Pathol; 2013 Sep; 66(9):779-86. PubMed ID: 23775437
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical determination of ETS-1 oncoprotein expression in urothelial carcinomas of the urinary bladder.
Sari A; Calli A; Gorgel SN; Altinboga AA; Kara C; Dincel C; Cakalagaoglu F
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):153-8. PubMed ID: 21623185
[TBL] [Abstract][Full Text] [Related]
20. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
